Faecal microbiota transplantation shortens the colonisation period and allows re-entry of patients carrying carbapenamase-producing bacteria into medical care facilities.


Journal

International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 04 06 2018
revised: 02 11 2018
accepted: 17 11 2018
pubmed: 26 11 2018
medline: 14 8 2019
entrez: 26 11 2018
Statut: ppublish

Résumé

Colonisation with carbapenemase-producing Enterobacteriaceae or Acinetobacter (CPE/A) is associated with complex medical care requiring implementation of specific isolation policies and limitation of patient discharge to other medical facilities. Faecal microbiota transplantation (FMT) has been proposed in order to reduce the duration of gut colonisation. This study investigated whether a dedicated protocol of FMT could reduce the negativation time of CPE/A intestinal carriage in patients whose medical care has been delayed due to such colonisation. A matched case-control retrospective study between patients who received FMT treatment and those who did not among CPE/A-colonised patients addressed for initial clustering at the current institute. The study adjusted two controls per case based on sex, age, bacterial species, and carbapenemase type. The primary outcome was delay in negativation of rectal-swab cultures. At day 14 post FMT, 8/10 (80%) treated patients were cleared for intestinal CPE/A carriage. In the control group, 2/20 (10%) had spontaneous clearance at day 14 after CPE/A diagnosis. Faecal microbiota transplantation led patients to reduce the delay in decolonisation (median 3 days post FMT for treated patients vs. 50.5 days after the first documentation of digestive carriage for control patients) and discharge from hospital (median 19.5 days post FMT for treated patients vs. 41 for control patients). Faecal microbiota transplantation is a safe and time-saving procedure to discharge CPE/A-colonised patients from the hospital. A standardised protocol, including 5 days of antibiotic treatment, bowel cleansing and systematic indwelling devices removal, should improve protocol effectiveness.

Sections du résumé

BACKGROUND BACKGROUND
Colonisation with carbapenemase-producing Enterobacteriaceae or Acinetobacter (CPE/A) is associated with complex medical care requiring implementation of specific isolation policies and limitation of patient discharge to other medical facilities. Faecal microbiota transplantation (FMT) has been proposed in order to reduce the duration of gut colonisation.
OBJECTIVES OBJECTIVE
This study investigated whether a dedicated protocol of FMT could reduce the negativation time of CPE/A intestinal carriage in patients whose medical care has been delayed due to such colonisation.
METHOD METHODS
A matched case-control retrospective study between patients who received FMT treatment and those who did not among CPE/A-colonised patients addressed for initial clustering at the current institute. The study adjusted two controls per case based on sex, age, bacterial species, and carbapenemase type. The primary outcome was delay in negativation of rectal-swab cultures.
RESULTS RESULTS
At day 14 post FMT, 8/10 (80%) treated patients were cleared for intestinal CPE/A carriage. In the control group, 2/20 (10%) had spontaneous clearance at day 14 after CPE/A diagnosis. Faecal microbiota transplantation led patients to reduce the delay in decolonisation (median 3 days post FMT for treated patients vs. 50.5 days after the first documentation of digestive carriage for control patients) and discharge from hospital (median 19.5 days post FMT for treated patients vs. 41 for control patients).
CONCLUSION CONCLUSIONS
Faecal microbiota transplantation is a safe and time-saving procedure to discharge CPE/A-colonised patients from the hospital. A standardised protocol, including 5 days of antibiotic treatment, bowel cleansing and systematic indwelling devices removal, should improve protocol effectiveness.

Identifiants

pubmed: 30472293
pii: S0924-8579(18)30339-X
doi: 10.1016/j.ijantimicag.2018.11.014
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Pagination

355-361

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Nadia Saïdani (N)

AP-HM, IHU-Méditerranée Infection, Marseille, France.

Jean-Christophe Lagier (JC)

AP-HM, IHU-Méditerranée Infection, Marseille, France; Aix Marseille Université, IRD, IHU-Méditerranée Infection, MEPHI, Marseille, France. Electronic address: jean-christophe.lagier@ap-hm.fr.

Nadim Cassir (N)

AP-HM, IHU-Méditerranée Infection, Marseille, France.

Matthieu Million (M)

AP-HM, IHU-Méditerranée Infection, Marseille, France; Aix Marseille Université, IRD, IHU-Méditerranée Infection, MEPHI, Marseille, France.

Sophie Baron (S)

AP-HM, IHU-Méditerranée Infection, Marseille, France; Aix Marseille Université, IRD, SSA, IHU-Méditerranée Infection, VITROME, Marseille, France.

Grégory Dubourg (G)

AP-HM, IHU-Méditerranée Infection, Marseille, France; Aix Marseille Université, IRD, IHU-Méditerranée Infection, MEPHI, Marseille, France.

Carole Eldin (C)

AP-HM, IHU-Méditerranée Infection, Marseille, France; Aix Marseille Université, IRD, IHU-Méditerranée Infection, MEPHI, Marseille, France.

Jad Kerbaj (J)

AP-HM, IHU-Méditerranée Infection, Marseille, France.

Camille Valles (C)

Aix Marseille Université, IRD, IHU-Méditerranée Infection, MEPHI, Marseille, France.

Didier Raoult (D)

AP-HM, IHU-Méditerranée Infection, Marseille, France; Aix Marseille Université, IRD, IHU-Méditerranée Infection, MEPHI, Marseille, France.

Philippe Brouqui (P)

AP-HM, IHU-Méditerranée Infection, Marseille, France; Aix Marseille Université, IRD, IHU-Méditerranée Infection, MEPHI, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH